Gain Therapeutics, Inc. (GANX) — SEC Filings
Gain Therapeutics, Inc. (GANX) — 36 SEC filings. Latest: 4 (Mar 27, 2026). Includes 26 8-K, 5 10-Q, 2 DEF 14A.
View Gain Therapeutics, Inc. on SEC EDGAR
Overview
Gain Therapeutics, Inc. (GANX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Mar 27, 2026: On March 24, 2026, Gain Therapeutics, Inc. (CIK: 0001819411) filed a Form 4, indicating changes in beneficial ownership of securities. The filing was accepted on March 26, 2026. The reporting person is Gene Mack, associated with CIK 0001737979.
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 3 bearish, 33 neutral. The dominant filing sentiment for Gain Therapeutics, Inc. is neutral.
Filing Type Overview
Gain Therapeutics, Inc. (GANX) has filed 1 4, 26 8-K, 5 10-Q, 2 DEF 14A, 2 10-K with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of GANX's 32 recent filings, 3 were flagged as high-risk, 16 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$10,339,145 |
| EPS | N/A |
| Debt-to-Equity | 1.66 |
| Cash Position | $6,694,136 |
| Operating Margin | N/A |
| Total Assets | $9,833,980 |
| Total Debt | $6,137,930 |
Key Executives
- Gene Mack
- 0001737979
- Chief Executive Officer
- Matthias Alder
- Dr. Marcella R. Ridgeway
- Ms. Jennifer L. Jones
- Dr. David M. Recker
- Ms. Jennifer L. Zimmerman
- Dr. Jonathan M. Roth
- Dr. Daniel J. O'Connell
Industry Context
Gain Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on rare genetic diseases. The industry is characterized by long drug development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and securing substantial funding for research and commercialization.
Top Tags
disclosure (7) · financials (7) · regulatory-filing (6) · 8-k (5) · corporate-governance (4) · 8-K (3) · executive-compensation (3) · material-agreement (3) · filing (3) · Gain Therapeutics (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for six months ended June 30, 2025 | $10,339,145 | Improved from $12,157,272 in prior year |
| Cash and cash equivalents as of June 30, 2025 | $6,694,136 | Decreased from $10,385,863 at December 31, 2024 |
| Total operating expenses for six months ended June 30, 2025 | $9,458,902 | Reduced from $12,560,524 in prior year |
| Research and development expenses for six months ended June 30, 2025 | $5,015,983 | Decreased from $6,944,537 in prior year |
| Net proceeds from ATM offering for six months ended June 30, 2025 | $4,910,240 | Source of financing |
| Accumulated deficit as of June 30, 2025 | $91,534,053 | Indicates significant historical losses |
| Foreign exchange loss for six months ended June 30, 2025 | $721,510 | Negative impact on other income (expense) |
| Common shares outstanding as of July 31, 2025 | 35,948,606 | Increased from 27,132,588 at December 31, 2024 |
| Additional Paid-In Capital | $28.7M | As of March 31, 2025, indicating capital raised from stock issuance. |
| Reporting Period End Date | 2025-03-31 | The end date for the financial data presented in this 10-Q. |
| Annual Meeting Date | 20250624 | Shareholders will vote on proposals at this date. |
| Filing Date | 20250429 | Date the proxy statement was officially submitted to the SEC. |
| Total Assets | $27.1M | As of December 31, 2024 |
| Total Liabilities | $16.2M | As of December 31, 2024 |
| SEC File Number | 001-40237 | Identifies the company's filing history with the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Gain Therapeutics, Inc. (GANX)?
Gain Therapeutics, Inc. has 36 recent SEC filings from Jan 2024 to Mar 2026, including 26 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GANX filings?
Across 36 filings, the sentiment breakdown is: 3 bearish, 33 neutral. The dominant sentiment is neutral.
Where can I find Gain Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Gain Therapeutics, Inc. (GANX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Gain Therapeutics, Inc.?
Key financial highlights from Gain Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GANX?
The investment thesis for GANX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Gain Therapeutics, Inc.?
Key executives identified across Gain Therapeutics, Inc.'s filings include Gene Mack, 0001737979, Chief Executive Officer, Matthias Alder, Dr. Marcella R. Ridgeway and 5 others.
What are the main risk factors for Gain Therapeutics, Inc. stock?
Of GANX's 32 assessed filings, 3 were flagged high-risk, 16 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Gain Therapeutics, Inc.?
Forward guidance and predictions for Gain Therapeutics, Inc. are extracted from SEC filings as they are enriched.